Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research note released on Friday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Trading Down 5.4 %

Shares of Galmed Pharmaceuticals stock opened at $1.59 on Friday. The stock’s fifty day moving average price is $2.37 and its 200-day moving average price is $3.37. The firm has a market cap of $1.02 million, a P/E ratio of -0.10 and a beta of 0.72. Galmed Pharmaceuticals has a 12 month low of $1.38 and a 12 month high of $23.80.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC bought a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals as of its most recent SEC filing. 76.14% of the stock is currently owned by institutional investors and hedge funds.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.